Drugs / eclitasertib
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 missed | ||||||
| Phase 1 | NCT04469621 | Jul → Oct 2020 | COVID-19 | Sanofi | Completed | Missed primary |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT05588843 | Nov 2022 → Feb 2026 overdue | ulcerative colitis | Sanofi | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04781816 | Apr 2021 → May 2023 | cutaneous lupus erythematosus | Sanofi | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-06-09 | Denali Therapeutics Inc. | Results Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With Sanofi denalitherapeutics.com ↗
Data from the completed Phase 1 study with peripherally-restricted RIPK1 inhibitor DNL758 in healthy volunteer subjects display an encouraging profile, as the molecule appears safe and tolerable at doses tested. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-06-28 | Denali Therapeutics Inc. | Denali Therapeutics Announces Initiation of Phase 2 Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in Cutaneous Lupus Erythematosus (CLE) Patients denalitherapeutics.com ↗ |
| 2020-07-29 | Denali Therapeutics Inc. | Denali Therapeutics Announces Phase 1b Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in COVID-19 Patients denalitherapeutics.com ↗ |
| 2020-06-09 | Denali Therapeutics Inc. | Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With Sanofi denalitherapeutics.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | eclitasertib | “This study explored the immunomodulatory and clinical effects of the receptor-interacting serine/threonine protein kinase 1 inhibitor SAR443122 (eclitasertib) in patients with...” PMID 38419035 ↗ Feb 2024 |
| Known as | DNL-758 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4861471 ↗ |
| Known as | SAR443122 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05588843 ↗ |
| Action | Inhibit | “(RIPK1) inhibitor” NCT04469621 ↗ |
| Modality | Small molecule | — CHEMBL4861471 ↗ |
| Route | Oral | “Route of administration: oral” NCT04469621 ↗ |
| Target | RIPK1 | “(RIPK1) inhibitor” NCT04469621 ↗ |